Study cohort characteristics for cases and controls
| . | Cases . | Controls . |
|---|---|---|
| Total, n | 3816 | 19 080 |
| Age, median (interquartile range), y | 69 (59-76) | 69 (59-76) |
| Age group, n (%), y | ||
| <60 | 981 (25.7) | 4905 (25.7) |
| 60-75 | 1755 (46.0) | 8775 (46.0) |
| >75 | 1080 (28.3) | 5400 (28.3) |
| Male sex, n (%) | 1875 (49.1) | 9375 (49.1) |
| Statin use before index date, n (%) | ||
| Never-user | 2484 (65.1) | 12 691 (66.5) |
| Ever-user | 1332 (34.9) | 6389 (33.5) |
| Long-term user (≥5 y) | 658 (17.2) | 3623 (19.0) |
| Highest achieved education, n (%) | ||
| Primary school | 1277 (33.5) | 6419 (33.6) |
| High school | 1576 (41.3) | 7608 (39.9) |
| Short/intermediate education | 659 (17.3) | 3394 (17.8) |
| Long education | 216 (5.7) | 1139 (6.0) |
| Charlson Comorbidity Index, n (%) | ||
| 0 | 3292 (86.3) | 17 614 (92.3) |
| 1 | 340 (8.9) | 1038 (5.4) |
| ≥2 | 184 (4.8) | 428 (2.2) |
| Medical history∗ , n (%) | ||
| Alcohol-related diagnoses | 262 (6.9) | 1104 (5.8) |
| Overweight- and obesity-related diagnoses | 155 (4.1) | 841 (4.4) |
| Chronic obstructive pulmonary disease | 348 (9.1) | 1527 (8.0) |
| AD | 325 (8.5) | 1611 (8.4) |
| Diabetes | 341 (8.9) | 1994 (10.5) |
| Previous drug use, n (%) | ||
| Aspirin | 1312 (34.4) | 5034 (26.4) |
| Other nonsteroidal anti-inflammatory drugs | 3140 (82.3) | 15 345 (80.4) |
| Metformin | 268 (7.1) | 1573 (8.2) |
| Alendronate | 242 (6.3) | 1114 (5.8) |
| Immunosuppressants | 95 (2.5) | 492 (2.6) |
| MPN subtype, n (%) | ||
| PV | 1306 (34.2) | N/A |
| ET | 1307 (34.3) | N/A |
| MF | 574 (15.0) | N/A |
| MPN-U | 629 (16.5) | N/A |
| . | Cases . | Controls . |
|---|---|---|
| Total, n | 3816 | 19 080 |
| Age, median (interquartile range), y | 69 (59-76) | 69 (59-76) |
| Age group, n (%), y | ||
| <60 | 981 (25.7) | 4905 (25.7) |
| 60-75 | 1755 (46.0) | 8775 (46.0) |
| >75 | 1080 (28.3) | 5400 (28.3) |
| Male sex, n (%) | 1875 (49.1) | 9375 (49.1) |
| Statin use before index date, n (%) | ||
| Never-user | 2484 (65.1) | 12 691 (66.5) |
| Ever-user | 1332 (34.9) | 6389 (33.5) |
| Long-term user (≥5 y) | 658 (17.2) | 3623 (19.0) |
| Highest achieved education, n (%) | ||
| Primary school | 1277 (33.5) | 6419 (33.6) |
| High school | 1576 (41.3) | 7608 (39.9) |
| Short/intermediate education | 659 (17.3) | 3394 (17.8) |
| Long education | 216 (5.7) | 1139 (6.0) |
| Charlson Comorbidity Index, n (%) | ||
| 0 | 3292 (86.3) | 17 614 (92.3) |
| 1 | 340 (8.9) | 1038 (5.4) |
| ≥2 | 184 (4.8) | 428 (2.2) |
| Medical history∗ , n (%) | ||
| Alcohol-related diagnoses | 262 (6.9) | 1104 (5.8) |
| Overweight- and obesity-related diagnoses | 155 (4.1) | 841 (4.4) |
| Chronic obstructive pulmonary disease | 348 (9.1) | 1527 (8.0) |
| AD | 325 (8.5) | 1611 (8.4) |
| Diabetes | 341 (8.9) | 1994 (10.5) |
| Previous drug use, n (%) | ||
| Aspirin | 1312 (34.4) | 5034 (26.4) |
| Other nonsteroidal anti-inflammatory drugs | 3140 (82.3) | 15 345 (80.4) |
| Metformin | 268 (7.1) | 1573 (8.2) |
| Alendronate | 242 (6.3) | 1114 (5.8) |
| Immunosuppressants | 95 (2.5) | 492 (2.6) |
| MPN subtype, n (%) | ||
| PV | 1306 (34.2) | N/A |
| ET | 1307 (34.3) | N/A |
| MF | 574 (15.0) | N/A |
| MPN-U | 629 (16.5) | N/A |
N/A, not applicable.
Markers per those given in supplemental Table 1.